Últimas noticias sobre Theriva Biologics (AMEX:TOVX) Bolsa

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics Inc

&nbsp;S&amp;P SmallCap 600 constituent SITE Centers Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) is spinning off Curbline Properties in a transaction expected to be completed on October 1.
Cross Country Healthcare is no longer representative of the small-cap market space.&nbsp;

News

CCRN

CURBw

SITC

Curbline Properties To Be Added To S&P SmallCap 600 Effective Prior To Open Of Trading On October 1, Replacing Cross Country Healthcare

TMDX

TransMedics Group To Replace Ensign Group In S&P SmallCap 600, Effective Prior To Opening Of Trading On October 1

&nbsp;S&amp;P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.&nbsp;

ENSG

Ensign Group Set To Join S&P MidCap 400, Effective Prior To Opening Of Trading On October 1, Replacing Southwestern Energy

As cannabis consumption becomes increasingly common across the U.S., a federal advisory panel is calling for a major shift in how the government handles <a href="https://www.benzinga.com/markets/cannabis/24/09/41049042/with-70-in-favor-could-nebraskas-cannabis-program-unlock-underserved-markets-local-expert-weighs">marijuana policy. </a>
Moving away from the &#8220;Just Say No&#8221; campaigns of the past, Thursday's report from the National Academies of Sciences, Engineering and Medicine advocates for a public health-focused approach, with the Centers for Disease Control and Prevention (CDC) playing a larger role than ever before, PBS News <a href="https://www.pbs.org/newshour/health/u-s-health-authorities-need-to-play-a-larger-role-in-cannabis-policy-report-says">reported.</a>
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/41053493/medical-marijuana-is-still-critical-balancing-act-between-recreational-medicinal-markets">&#8216;Medical Marijuana is Still Critical&#8217;: Balancing Act Between Recreational, Medicinal Markets</a>
<h3 class="wp-block-heading">A Health-Centric Shift In Cannabis Policy</h3>
"We'd like the federal government to step up to provide some leadership in this area," said Dr. Steven Teutsch of the University of Southern California, who chaired the committee behind the report. 
The CDC and the National Institutes of Health (NIH) sponsored the findings, which suggest that the rise of stronger cannabis products coupled with higher rates of daily use necessitate a more robust federal response.
A CDC spokesperson confirmed that the agency is reviewing the report&#8217;s recommendations but stressed that additional funding would be needed to implement them effectively.
<h3 class="wp-block-heading">Escalating Cannabis Potency Raises Public Health Concerns</h3>
One of the report&#8217;s key concerns is the increasing potency of marijuana. "Now you go into the stores, it's hard to find products that are less than 20% THC," noted Beau Kilmer, co-director of the RAND Drug Policy Research Center and a member of the report committee. 
This sharp increase from the roughly 5% THC levels seen 25 years ago has raised alarms over the risks associated with heavy cannabis use, including car accidents and <a href="https://www.benzinga.com/markets/cannabis/23/02/30877367/long-term-marijuana-use-can-lead-to-rare-condition-cannabinoid-hyperemesis-syndrome-say-physic-1">cannabis hyperemesis syndrome</a>, a condition that causes severe vomiting and often requires emergency medical care.
For younger users, the risks extend beyond physical health. According to the report, regular cannabis use among teenagers may interfere with learning and increase the likelihood of developing mood and anxiety disorders. Pregnant women who use cannabis regularly also risk complications for their babies.
<h3 class="wp-block-heading">Cannabis Industry Pushback</h3>
Furthermore, the report notes that cannabis industry lobbying has played a significant role in shaping state policies. In states like Washington and Colorado, efforts to limit THC concentrations or restrict the use of pesticides in cultivation have been met with resistance.
However, Aaron Smith, CEO of the National Cannabis Industry Association, defended the regulated market. "States have protected public health by replacing criminal markets with regulated businesses that are required to test products for contaminants, practice truth in labeling, and most importantly, keep cannabis products out of the hands of minors," said Smith. 
Smith added that legalizing cannabis nationally would allow for more comprehensive federal regulations, ultimately improving public health.
<h3 class="wp-block-heading">Key Recommendations From The Report</h3>
The advisory panel outlined several recommendations aimed at improving cannabis-related public health measures:
<ul>
<li>CDC: Develop and evaluate health campaigns specifically aimed at parents, teens, pregnant women, and older adults. Additionally, the agency should monitor cannabis cultivation, sales, and usage trends, while also establishing best practices for state regulations.</li>
<li>Congress: The report calls for closing a loophole that allows intoxicating hemp-derived products to be sold in states where other cannabis products remain illegal. Congress should also lift restrictions that prevent the Office of National Drug Control Policy from studying the effects of cannabis legalization.</li>
<li>States: Recommendations include requiring cannabis retail staff to undergo training and certification, expunging records for low-level cannabis-related offenses, and adopting U.S. Pharmacopeia quality standards for cannabis products.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41034042/fbi-report-over-200-000-people-were-arrested-for-cannabis-related-violations-in-2023-how-is-that">FBI Report Over 200,000 People Were Arrested For Cannabis-Related Violations In 2023: How Is That Possible?</a></li>
</ul>

Cannabis

Health Care

Markets

Federal Health Agencies Must Take Stronger Role In U.S. Cannabis Policy Shift, New Report Says

Management

TFPM

Triple Flag Precious Metals Appoints Sheldon Vanderkooy As CEO And Director, Succeeding Shaun Usmar Who Departs Effective On September 26, 2024

Michael Garcia, Algoma&#39;s Chief Executive Officer, stated, &quot;Our operations are performing in line with expectations for the fiscal&nbsp;second quarter, despite operating against a backdrop of challenging market conditions for steel demand and pricing.&quot;

Guidance

ASTL

Algoma Steel Expects Q2 Total Steel Shipments Of 510,000 To 520,000 Tons; Says Operations Are Performing In Line With Expectations For The Quarter

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported second-quarter financial results Thursday after the bell. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/09/ac41057250/blackberry-reports-second-quarter-fiscal-year-2025-results">rundown of the report</a>.
Q2 Earnings: BlackBerry reported second-quarter revenue of $145 million, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $141.42 million. The company reported breakeven second-quarter earnings on an adjusted basis, beating analyst estimates for a loss of 3 cents per share, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
IoT revenue was&nbsp;$55&nbsp;million, up 12% year-over-year.&nbsp;Cybersecurity revenue totaled $87&nbsp;million in the quarter, up 10% year-over-year. Licensing revenue&nbsp;came in at $3&nbsp;million. 
BlackBerry ended the quarter with $265 million in&nbsp;cash, cash equivalents and&nbsp;short-&nbsp;and long-term investments.
&#8220;BlackBerry reached a significant milestone on our path to profitability by recording breakeven adjusted EBITDA and non-GAAP EPS. This result was achieved through a combination of stronger-than-expected, double-digit revenue growth for both IoT and Cybersecurity, as well as tremendous ongoing progress in rationalizing our cost structure. Operating expenses for the quarter were 24% lower than the baseline for the prior year,&#8221; said John Giamatteo, CEO of BlackBerry.
&#8220;QNX delivered strong royalty revenue again this quarter, and there was year-over-year revenue growth for the secure communications products in our Cybersecurity division.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/09/41016947/crowdstrike-executive-struck-by-regret-in-house-hearing-says-company-determined-to-prevent-instances">CrowdStrike Executive Struck By Regret In House Hearing, Says Company Determined To Prevent Instances Like Microsoft Outage From Repeating: &#8216;Deeply Sorry This Happened&#8217;</a>
What&#8217;s Next: BlackBerry expects third-quarter revenue of $146 million to $154 million. BlackBerry sees third-quarter IoT revenue of $56 million to $60 million, cybersecurity revenue of $86 million to $90 million and licensing and other revenue of approximately $4 million. 
The company also guided for breakeven third-quarter earnings, plus or minus one cent per share.
BlackBerry anticipates full-year revenue of $591 million to $616 million. The company anticipates a full-year adjusted earnings loss of 2 cents to 5 cents per share.
Management will hold a conference call to discuss these results at 5:30 p.m. ET.
BB Price Action: <a href="https://www.benzinga.com/quote/BB" target="_blank" rel="noreferrer noopener">BlackBerry shares</a> were up 0.79% in after-hours, trading at $2.56 at the time of publication Thursday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of BlackBerry.

Earnings

After-Hours Center

Movers

BlackBerry Q2 Earnings: Revenue, EPS Beat Estimates Driven By Strength In IoT, Cybersecurity

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual return of 12.86%. Currently, AbbVie has a market capitalization of $338.87 billion. 
Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 10 years ago, it would be worth $3,322.37 today based on a price of $191.90 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727386222_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ABBV

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) has outperformed the market over the past 10 years by 31.24% on an annualized basis producing an average annual return of 42.65%. Currently, Fair Isaac has a market capitalization of $47.17 billion. 
Buying $100 In FICO: If an investor had bought $100 of FICO stock 10 years ago, it would be worth $3,491.49 today based on a price of $1923.81 for FICO at the time of writing.
<h3>Fair Isaac's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727386217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FICO

$100 Invested In Fair Isaac 10 Years Ago Would Be Worth This Much Today

Offerings

Scotiabank Issues C$1.25B, Five-year Sustainability Notes On September 26

The 1-for-15 ratio is within the range approved by the Company&#39;s stockholders at the Special Meeting of Stockholders held on September 19, 2024.

Stock Split

STRM

Streamline Health Plans To Proceed With 1-For-15 Reverse Stock Split Of Its Outstanding Shares Of Common Stock

On September 25, 2024, the board of directors appointed Campbell Becher as President of the Company, effective immediately.
On September 26, 2024, the board of directors appointed Kevin Richardson as Interim Chief Executive Officer and Chief Financial Officer as well as a member of the board of directors.&nbsp;

Qualigen Therapeutics, Inc. - Common Stock

QLGN

Qualigen Therapeutics Says CEO & Chairman Michael Poirier And CFO Christopher Lotz Resign Due To Disagreements With Company Regarding Its Future Direction And Strategic Initiatives

Real Good Food Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGF#NASDAQ">RGF</a>) shares are racing higher in extended trading Thursday after the company announced debt refinancing transactions with PMC Financial Services and Emblem Investment Fund<a href="https://www.benzinga.com/pressreleases/24/09/g41055786/the-real-good-food-company-announces-debt-refinancing-transactions-with-pmc-financial-services-and"> for a $60 million new term loan.</a>
The Details: The company said it will apply $8 million of the proceeds to repay the existing PMC financing and $52 million for transaction fees and general corporate purposes to support the expansion of its manufacturing capabilities and drive several corporate initiatives to position the company for profitable long-term growth. 
Additionally, as part of the agreement, the company issued 19.99% of its outstanding equity to Emblem in the form of Class C Units of its subsidiary, Real Good Food LLC, which are exchangeable into the company&#8217;s common shares.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41036580/expect-healthy-online-spending-this-holiday-season-says-analyst-what-to-know">Expect Healthy Online Spending This Holiday Season, Says Analyst: What To Know</a>
&#8220;We are thrilled to announce these transformational transactions, which provide us with significant liquidity and therefore the capability to make critical investments in our supply chain and strategic initiatives. This will better position our supply chain to meet strong demand for our products and improve service for our customers, which sets the foundation for profitable long-term growth,&#8221; said Tim Zimmer, CEO of Real Good Foods.&nbsp;
Real Good Food Company shares are moving on heavy trading volume following the announcement with more than 7.6 million shares traded in Thursday's session, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.  
RGF Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, the Real Good Food Company shares are up 66.76% after-hours at 62 cents at the time of publication Thursday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41028294/whats-going-on-with-snowflake-stock">What&#8217;s Going On With Snowflake Stock?</a></li>
</ul>
Photo: Gerd Altmann from Pixabay

Penny Stocks

What's Going On With Real Good Food Company Stock?

This action is consistent with the Company&#39;s capital allocation framework, which returns at least&nbsp;50 percent&nbsp;of post base dividend Non-GAAP Free Cash Flow to shareholders.

Buybacks

Ovintiv Receives Regulatory Approvals For Renewal Of Its Share Buy-back Program

ESTA

Establishment Labs Receives FDA Approval For Use Of Motiva SmoothSilk Ergonomix And Motiva SmoothSilk Round Breast Implants In Primary And Revision Breast Augmentation

ALRS

HMNF

Alerus Financial Says It Received All Regulatory Approvals Necessary To Complete Acquisition Of HMN Financial

LGCL

Lucas GC Limited H1 Revenue $83.32M, Down From Prior Year

MNTS

Momentus Receives Non-Compliance Notice From Listing Qualifications Department Of Nasdaq

BlackBerry Revises FY25 Total BlackBerry Revenue Forecast From $586M - $616M To $591M - $616M, Est $604.35M; Adj Basic EPS Guidance From $(0.03) – $(0.07) To $(0.05) - $(0.02), Est $(0.04)

A groundbreaking study from New York&#8217;s Columbia University suggests that <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a>, the psychoactive compound in magic mushrooms may offer relief to individuals suffering from body dysmorphic disorder (BDD). The research, <a href="https://pp.genomicpress.com/wp-content/uploads/2024/09/PP0028-Zhu-2024.pdf">published</a> in Psychedelics, explored the effects of psilocybin on brain function in BDD patients, revealing significant changes in brain connectivity that may alleviate the obsessive thought patterns central to the disorder.
<h3 class="wp-block-heading">Body Dysmorphic Disorder: More Than Skin Deep</h3>
BDD is a mental health condition marked by an obsessive focus on perceived physical flaws, often leading to distress and isolation. Traditional treatments, including cognitive-behavioral therapy and antidepressants, have offered limited success for many. In this new study, eight adults with moderate-to-severe BDD received a single 25 mg dose of psilocybin, followed by brain scans and symptom assessments. The study was supported by COMPASS Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) and conducted using the company&#8217;s proprietary synthetic formulation, COMP360.
<h3 class="wp-block-heading">Study Reveals Long-Lasting Symptom Relief</h3>
Results showed increased brain connectivity, especially within the Executive Control Network (ECN), which is essential for cognitive flexibility and goal-directed behavior. The ECN also enhanced its connections with the Default Mode Network, associated with self reflection and the Salience Network, which helps prioritize information. These changes predicted a noticeable reduction in BDD symptoms, maintained for up to 12 weeks post-treatment.
<h3 class="wp-block-heading">A Step Forward, But More Research Is Needed</h3>
While the study offers hope, the researchers, including lead author Dr. Xi Zhu, caution that larger controlled trials are needed to confirm psilocybin&#8217;s efficacy as a treatment for BDD. The small sample size and absence of a placebo group limit the study's conclusions. Still, the findings represent a promising step toward using psychedelics to address conditions resistant to conventional therapies.
Convert image made with AI

Psychedelics

CMPS

Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder

Theriva Biologics (TOVX) has provided an announcement. Theriva Biologics, Inc. has received Rare Pediatric Drug Designation from the FDA for its le...

Theriva Biologics Gains FDA Nod and Converts Preferred Stock

Theriva Biologics GAAP EPS of -$0.43

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Theriva Biologics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tovx-stock-quote/">TOVX</a>) just reported results for the second quarter of 2024.<ul><li>Theriva Biologics reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -28 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tovx-stock-earnings-theriva-biologics-for-q2-of-2024/">TOVX Stock Earnings: Theriva Biologics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TOVX Stock Earnings: Theriva Biologics Beats EPS for Q2 2024

Maxim Group analyst Jason McCarthy maintained a Buy rating on Theriva Biologics (TOVX – Research Report) yesterday. The company's shares opened tod...

Maxim Group Remains a Buy on Theriva Biologics (TOVX)

Theriva biologics announces 1:25 reverse stock split

These are the upcoming stock splits for the week of August 26 to August 30, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a corpo...

Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested

Theriva Biologics ($TOVX) is making noise in the field of immuno-oncology, supported by a promising pipeline. The stock is up 79% in the past few d...

Theriva Biologics (TOVX) Is Making Noise With a Promising Pipeline

Theriva Biologics files for common stock offering

Theriva Biologics ( ($TOVX) ) has provided an update. Theriva Biologics, Inc. has received a €2.28 million boost from the Spanish government to enh...

Theriva Biologics Secures Funding for Viral Therapy Innovation

Theriva Biologics ( ($TOVX) ) has shared an update. Theriva Biologics, Inc. is actively engaging with investors and discussing their lead product c...

Theriva Biologics Advances VCN-01 in VIRAGE Phase 2b Trial

FBRX

GDEV

OBLG

TOVX

Screenshot 2024-08-23 at 5.34.20 PM

Biotech

General

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-28 at 6.54.06 PM

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Press Releases

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results

Theriva Biologics Announces Reverse Stock Split

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Comments

Theriva Biologics

Noticias

Últimas noticias sobre Theriva Biologics (AMEX:TOVX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL